SCLX Key Statistics, Chart & Performance
The current stock price of SCLX is 18.75 USD. In the past month the price increased by 4.98%. In the past year, price decreased by -17.2%.
SCLX Latest News, Press Relases and Analysis
SCLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About SCLX
Company Profile
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 31 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Company Info
SCILEX HOLDING CO
960 San Antonio Road
Palo Alto CALIFORNIA US
Employees: 31
Phone: 16505164310
SCILEX HOLDING CO / SCLX FAQ
Can you describe the business of SCILEX HOLDING CO?
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 31 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
What is the current price of SCLX stock?
The current stock price of SCLX is 18.75 USD. The price decreased by -3.65% in the last trading session.
What is the dividend status of SCILEX HOLDING CO?
SCLX does not pay a dividend.
What is the ChartMill rating of SCILEX HOLDING CO stock?
SCLX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists SCLX stock?
SCLX stock is listed on the Nasdaq exchange.
What is the market capitalization of SCLX stock?
SCILEX HOLDING CO (SCLX) has a market capitalization of 142.31M USD. This makes SCLX a Micro Cap stock.
Can you provide the upcoming earnings date for SCILEX HOLDING CO?
SCILEX HOLDING CO (SCLX) will report earnings on 2026-03-30, before the market open.
SCLX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to SCLX. When comparing the yearly performance of all stocks, SCLX is a bad performer in the overall market: 81.93% of all stocks are doing better.
SCLX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SCLX. SCLX may be in some trouble as it scores bad on both profitability and health.
SCLX Financial Highlights
Over the last trailing twelve months SCLX reported a non-GAAP Earnings per Share(EPS) of -20.3.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -164.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCLX Forecast & Estimates
6 analysts have analysed SCLX and the average price target is 499.8 USD. This implies a price increase of 2565.6% is expected in the next year compared to the current price of 18.75.
For the next year, analysts expect an EPS growth of 80.66% and a revenue growth 84.5% for SCLX